RxDoctor Payments DataLook up a doctor →

Ajay Veeragandham, MD

Psychiatry · Jacksonville, NCNPI 1558467571

Payments from drug & device makers

$21,317in general payments, 2019–2025

Across 1,403 payments — averaging $15.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$2K
  • AbbVie$2K
  • Teva Pharmaceuticals USA, Inc.$2K
  • Alkermes, Inc.$2K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
  • Johnson & Johnson$2K
  • plus $10K from 32 others

What the payments were for

  • Food & beverage$21,02699%
  • Education$2911%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,317 in reported general payments places this provider in the 95th percentile of 1,108 psychiatry providers in North Carolina.

See all psychiatry providers in North Carolina

Medicare billing

Part B allowed, 2024
$49,134
Medicare patients
122
Services billed
393

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate16$57,507
VraylarCariprazine Hcl28$52,187
RexultiBrexpiprazole15$27,477
FanaptIloperidone11$18,421
Clozapine OdtClozapine11$12,206
Lurasidone Hcl86$5,648
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine117$5,287
VyvanseLisdexamfetamine Dimesylate13$4,900
Ziprasidone Hcl59$3,276
Olanzapine-Fluoxetine HclOlanzapine/Fluoxetine Hcl14$3,121
Aripiprazole146$2,864
Quetiapine Fumarate148$2,498
Clonazepam300$2,487
Paliperidone ErPaliperidone17$2,462
Buspirone Hcl230$2,239

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$1,579$57,50716 claims
AbbVieVraylar$2,224$52,18728 claims
Otsuka America Pharmaceutical, Inc.Rexulti$2,416$27,47715 claims
Vanda Pharmaceuticals Inc.Fanapt$724$18,42111 claims
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse$388$4,90013 claims
Almatica Pharma LLCSertraline Hcl$787$496134 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,108 psychiatry providers in North Carolina.

Other psychiatry in Jacksonville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →